Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Treatment/Intervention:  oncolytic virotherapy
Results 1-25 of 26 for your search:
Start Over
PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PV-10-MM-31, NCI-2015-00568, NCT02288897
Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: BOND 2 version 3.7, NCI-2015-01830, BOND 2 version 3.4, BOND 2 version 3.5, NCT02365818
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: JX594-HEP024, NCI-2016-00198, NCT02562755
MV-NIS Infected Mesenchymal Stem Cells in Treating Patients with Recurrent Ovarian Cancer
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1266, NCI-2014-00016, NCT02068794
Talimogene Laherparepvec and Preoperative Radiation Therapy in Treating Patients with Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201504731, NCI-2015-01193, 20139075, NCT02453191
Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 20110266, NCI-2015-00229, 2014-001146-13, NCT02211131
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients with Ovarian, Fallopian, or Peritoneal Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1365, NCI-2015-00133, NCT02364713
Talimogene Laherparepvec in Treating Patients with Recurrent Breast Cancer That Cannot Be Removed by Surgery
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0034, NCI-2016-00199, NCT02658812
Viral Therapy in Treating Patients with Recurrent Glioblastoma Multiforme
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC0671, NCI-2009-01198, MAYO-MC0671, MAYO-06-004440, NCT00390299
Oncolytic HSV1716 in Treating Patients with Refractory Non-Central Nervous System Solid Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 13 to 30
Trial IDs: OSU-08196, NCI-2016-00251, IRB13-00471, NCT00931931
Oncolytic HSV-1 rRp450 in Treating Patients with Primary Liver Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 09-042, NCI-2010-01930, NCT01071941
Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: REO 022, NCI-2012-00474, NCT01274624
Recombinant Oncolytic Poliovirus PVS-RIPO in Treating Patients with Recurrent Grade IV Malignant Glioma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00031169, NCI-2013-01899, NS20023, PVSRIPO, NCT01491893
Intrapleural Measles Virus Therapy in Treating Patients with Malignant Pleural Mesothelioma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1023, NCI-2011-03574, 2010UC103, Mod1000260438, NCT01503177
Viral Therapy in Treating Patient With Liver Cancer
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1148, NCI-2012-00890, 11-007114, NCT01628640
Viral Therapy in Treating Patients with Primary, Metastatic, or Mesothelioma-Related Malignant Pleural Effusion
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-169, NCI-2013-00105, GL-ONC1-003/MSKCC, MSKCC-12169, NCT01766739
Viral Therapy In Treating Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC0979, NCI-2013-00811, NCT01846091
Oncolytic HSV-1716 in Treating Younger Patients with Refractory or Recurrent High Grade Glioma That Can Be Removed by Surgery
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 to 21
Trial IDs: PBTC-037, NCI-2013-00526, NCT02031965
DNX-2401 With Interferon Gamma (IFN-?) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2401BT-IFN-001, NCI-2014-01929, NCT02197169
Wild-Type Reovirus in Combination with Sargramostim in Treating Younger Patients with High-Grade Recurrent or Refractory Brain Tumors
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 10 to 21
Trial IDs: MC1472, NCI-2015-00665, MC1472 / Mayo IRB 14-006414, Mod14-006414-01, NCT02444546
Safety Study of Talimogene Laheraprepvec Injected Into Hepatocellular Carcinoma and Metastatic Liver Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 20140318, NCI-2015-02069, 2014-005386-67, NCT02509507
Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: REO 024, NCI-2015-02218, NCT02620423
Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16M-15-2, NCI-2015-01069, REO 019, NCT02514382
Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: MC1372, NCI-2016-00179, NCT02700230
Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 20130232, NCI-2016-00537, NCT02626000
Start Over